Melanotan-II vs PT-141 · Mechanism, Dose, Cited Research

Side-by-side

	Melanotan-II	PT-141
Mechanism	Non-selective melanocortin-receptor agonist.	Selective MC4-receptor agonist (bremelanotide); FDA-approved for HSDD.
Half-life	Short.	Short.
Dose	250-500 mcg/day SC (loading).	1-1.75 mg SC as needed.
Cycle	2-week loading + maintenance.	PRN (as needed).
Research context	Melanogenesis and off-target MC-receptor effects¹.	FDA-approved for HSDD; RECONNECT trial data².
Cost tier	Low.	Mid-to-high.

Melanotan-II and PT-141 share a melanocortin-receptor-agonist origin. The difference is selectivity. Melanotan-II hits multiple melanocortin receptors (MC1, MC3, MC4, MC5) with activities including melanogenesis, appetite suppression, sexual-function effects, and various off-target endocrine effects¹. PT-141 (bremelanotide) was specifically engineered for MC4-receptor selectivity, which isolates the sexual-function activity from melanogenesis².

Clinical context is where the difference becomes concrete. PT-141 is FDA-approved for hypoactive sexual desire disorder in premenopausal women based on the RECONNECT trial. Dosing is 1.75 mg subcutaneously as needed, not on a continuous schedule. Melanotan-II is a research peptide with no clinical registration; the pigmentation effect it produces is the reason for most research interest, but the off-target MC-receptor activity is what limits it for therapeutic use.

Research-protocol selection is determined by the endpoint. Sexual-function research with a clinical comparator uses PT-141. Melanogenesis research uses Melanotan-II, with explicit accounting for the off-target effects (appetite, MC3/MC5 activity, pigmentation-related cancer screening in the research design). Both warrant careful contraindication review; Melanotan-II is specifically cautioned in atypical-mole or melanoma-history contexts, and PT-141 in uncontrolled-hypertension contexts. See best peptides for fat loss for the broader body-recomposition class context.

Frequently asked

Why is PT-141 FDA-approved but Melanotan-II is not?

PT-141 was engineered for MC4-receptor selectivity, isolating the sexual-function effect from melanogenesis and off-target MC-receptor activity. That selectivity allowed clean trial design. Melanotan-II's broad agonism produces too many off-target effects for a selective clinical indication.

Can they substitute for each other?

No. PT-141 is selective for sexual-function research. Melanotan-II is broader and produces pigmentation and appetite effects that PT-141 does not. They target different research questions.

What are the key contraindications?

Melanotan-II is specifically cautioned with atypical moles or melanoma history because of melanogenesis activity. PT-141 is specifically cautioned in uncontrolled hypertension because of transient blood-pressure effects.

Research desk

Ordering both Melanotan-II and PT-141 for a research protocol? The Bangkok desk handles pricing, COA, and timing on WhatsApp.

Open a line with the research desk ≥98% HPLC purity · supplier COA on file · Bangkok-based

Go deeper

Related comparisons

Comparison 5-Amino-1MQ vs AOD-9604 5-Amino-1MQ vs AOD-9604: oral NNMT inhibitor vs hGH-fragment lipolytic peptide. Two body-recomposition mechanisms compared with cited research.

References

Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996. PMID: 8637402
Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (RECONNECT). Obstet Gynecol. 2019. PMID: 31599840

All references verified against PubMed via NCBI E-utilities.